Achaogen (AKAO) Reaches New 1-Year Low at $1.70

Share on StockTwits

Shares of Achaogen Inc (NASDAQ:AKAO) reached a new 52-week low on Wednesday . The stock traded as low as $1.70 and last traded at $1.87, with a volume of 878217 shares changing hands. The stock had previously closed at $1.93.

AKAO has been the topic of several recent research reports. Mizuho restated a “neutral” rating and set a $8.00 price target on shares of Achaogen in a report on Tuesday, November 6th. Stifel Nicolaus increased their price target on Achaogen from $14.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, August 7th. Zacks Investment Research upgraded Achaogen from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a report on Wednesday, October 10th. Wedbush lowered Achaogen from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $17.00 to $3.00 in a report on Monday. Finally, Cowen lowered Achaogen from an “outperform” rating to a “market perform” rating in a report on Friday, November 9th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $9.25.

The stock has a market cap of $89.01 million, a P/E ratio of -0.50 and a beta of 0.67. The company has a quick ratio of 2.52, a current ratio of 2.54 and a debt-to-equity ratio of 1.00.

A number of institutional investors have recently made changes to their positions in the business. AXA grew its position in Achaogen by 31.4% in the 3rd quarter. AXA now owns 903,425 shares of the biopharmaceutical company’s stock valued at $3,605,000 after acquiring an additional 215,989 shares during the last quarter. Gabelli Funds LLC grew its position in Achaogen by 48.7% in the 3rd quarter. Gabelli Funds LLC now owns 306,900 shares of the biopharmaceutical company’s stock valued at $1,225,000 after acquiring an additional 100,500 shares during the last quarter. JPMorgan Chase & Co. grew its position in Achaogen by 2,745.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 294,768 shares of the biopharmaceutical company’s stock valued at $1,176,000 after acquiring an additional 284,407 shares during the last quarter. Teton Advisors Inc. grew its position in Achaogen by 85.0% in the 3rd quarter. Teton Advisors Inc. now owns 259,000 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 119,000 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Achaogen in the 3rd quarter valued at $823,000. 61.10% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://weekherald.com/2018/11/16/achaogen-akao-reaches-new-1-year-low-at-1-70.html.

Achaogen Company Profile (NASDAQ:AKAO)

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

See Also: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply